Cardiometabolic
Cholesterol and Lipids on a GLP-1
Triglycerides fall a long way, HDL rises a little, and LDL barely moves — which surprises people who assumed losing weight fixes cholesterol. Here is what changes, what does not, and why your statin stays.
People arrive at the six-month blood test expecting the whole panel to be transformed, and are quietly disappointed. The panel does improve. It improves unevenly, and understanding the pattern prevents a lot of unnecessary worry and one genuinely bad decision.
What moves, and by how much
| Measure | Response to weight loss | Why |
|---|---|---|
| Triglycerides | Largest, fastest | Tightly linked to insulin resistance and visceral fat |
| HDL | Modest rise | Slow to move; improves with weight and activity |
| LDL | Small reduction | Driven by hepatic handling and genetics more than weight |
| Non-HDL / ApoB | Improves with triglycerides | Often the more useful measure |
| Lipoprotein(a) | No change | Genetically determined |
Triglycerides are the headline, and they move within 3–6 months rather than years. They track insulin resistance and visceral fat closely, and they frequently fall substantially within months. If yours were high, this is where you will see the change — and it matters clinically, because very high triglycerides are themselves a cause of pancreatitis, which is discussed in the pancreatitis warning explained.
LDL is the disappointment, and it is worth expecting rather than being surprised by. Weight loss produces modest LDL reductions. That is not a failure of your treatment; it is what LDL does.
Why your statin stays
This is the bad decision I want to head off.
Statins are not prescribed to make a number look tidy. They reduce cardiovascular events, and the evidence for that is among the largest in medicine — the Cholesterol Treatment Trialists’ meta-analyses cover many tens of thousands of participants.
The people on them generally have a risk profile that weight loss improves but does not erase: established cardiovascular disease, type 2 diabetes, a high calculated risk, or familial hypercholesterolaemia. Losing 15% of your body weight is genuinely excellent for that risk. It does not undo the arterial disease already present.
So: an improved LDL on a statin means the statin is working, not that it is no longer needed. Stopping it is a conversation, not a conclusion — and the framing in the heart data applies here too. These drugs and statins are complementary, and the cardiovascular benefit shown in SELECT was on top of background lipid therapy, not instead of it.
If your LDL stays high
Worth investigating rather than waiting out.
Familial hypercholesterolaemia is substantially underdiagnosed, affects roughly 1 in 250 people and raises lifetime cardiovascular risk substantially, and is the situation where treatment matters most and is most often delayed. The clues: an LDL that stays high despite weight loss and treatment, a family history of early heart disease, or a relative who had an event in their forties or fifties.
If that describes you, ask directly. It changes both your treatment intensity and whether your relatives need screening.
The test nobody has had
Lipoprotein(a).
It is an independent cardiovascular risk factor, largely genetically determined, and it does not respond meaningfully to weight loss, diet or statins. Many guidelines now support measuring it once in adulthood.
The reason to bother: a high result changes how aggressively everything else should be treated, and it identifies a family who should be tested. The reason it is worth doing now: you are already having blood taken, and the result never needs repeating.
Most people have never been offered it. Ask — it belongs on the list in reading your own labs.
Timing and what to measure
Do not test too early. Lipids move over months, not weeks. A panel at week six tells you about the week you had, not about your treatment. Baseline, then around 6 months, then every 12 months is a reasonable rhythm.
Fasting is usually unnecessary for a standard panel under current guidance, though a 9–12 hour fast still sharpens a triglyceride measurement, though your lab may still ask. If triglycerides are the specific question, fasting improves the measurement.
Ask for ApoB or non-HDL cholesterol alongside the standard panel. Non-HDL is calculated from numbers you already have, and both give a better picture of atherogenic particles than LDL alone — particularly when triglycerides are high, which is exactly this population.
What else is doing the work
Weight loss is one input among several, and the others have not stopped mattering:
- Resistance and aerobic training — 2 sessions and roughly 150 minutes a week — improve triglycerides and HDL independently of weight — cardio, steps and heart rate
- Alcohol raises triglycerides directly, and often falls on this drug without anyone trying — drinking alcohol on a GLP-1
- Fatty liver and lipid abnormalities travel together, and both improve with the same intervention — GLP-1s and fatty liver disease
- Thyroid function affects lipids, and an untreated underactive thyroid raises LDL — worth excluding if the numbers make no sense
What to ask for
- Baseline lipids before starting, so later results mean something
- ApoB or non-HDL alongside the standard panel
- Lipoprotein(a) once, ever
- A repeat at around 6 months, not at week six
- An explicit conversation about why you are on a statin, if you are, before any thought of stopping it
- Investigation if LDL stays high despite substantial weight loss
Questions I get about this month
- Does a GLP-1 lower cholesterol?
- It improves the lipid panel, and unevenly. Triglycerides respond most, often falling substantially as weight and insulin resistance improve. HDL rises modestly. LDL cholesterol changes least — typically a small reduction that disappoints people expecting normalisation. That pattern is characteristic of weight loss generally rather than specific to these drugs, and it is why weight loss complements lipid-lowering therapy rather than replacing it.
- Can I stop my statin if my cholesterol improves?
- That is a decision about cardiovascular risk rather than about a number, and it belongs to your prescriber. Statins reduce cardiovascular events through mechanisms beyond LDL lowering, and the people prescribed them usually have a risk profile that weight loss improves but does not erase — established cardiovascular disease, diabetes, or a high calculated risk. Stopping because a lab value looks better is one of the more common self-directed decisions that later turns out badly.
- Why did my LDL not improve after losing weight?
- Because LDL is the lipid least responsive to weight loss. It is driven substantially by hepatic cholesterol handling and by genetics, and modest reductions are the norm rather than dramatic ones. If your LDL is high and staying high despite substantial weight loss, that is worth investigating rather than waiting out — familial hypercholesterolaemia is underdiagnosed, and it is the situation where treatment matters most and is most often delayed.
- What is lipoprotein(a) and should I have it measured?
- Lipoprotein(a) is an independent, largely genetically determined cardiovascular risk factor that does not meaningfully respond to weight loss, diet or statins. Many guidelines now support measuring it once in adulthood, because the result changes how aggressively other risk factors are treated and it identifies families who need screening. It is a single test you never have to repeat, and most people have never been offered it.
Sources
- 01Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
- 02Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023.
- 03Grundy SM et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation, 2019.
- 04Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol. The Lancet, 2010.
- 05Wilson DP et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. Journal of Clinical Lipidology, 2019.
Elise Hall, MD
Board-certified internist in Los Angeles, twenty-one years in practice. She writes about GLP-1 medications and metabolic health for people who want the reasoning, not just the conclusion — and publishes her own year on one of these drugs alongside it.
Keep reading
Supplements
The Best Supplements for GLP-1 Hair Loss
The shedding starts two to four months after the loss speeds up, which is why almost nobody connects the two. Seven supplements ranked — and one of them interferes with the blood test that rules out a heart attack.
Supplements
Best Bone Health Supplements on a GLP-1
Bone is the tissue nobody thinks about until a wrist breaks. Rapid weight loss reduces bone mineral density, the effect is largest in exactly the people most likely to be prescribed these drugs, and none of it produces a symptom until it does.
Tools
The Best GLP-1 Apps, Ranked
I scored every tracker I could get my hands on against seven criteria that matter specifically on a GLP-1 — not generic calorie counting. Here is the ranking, the rubric behind it, and where my first choice falls short.